Skip to main content
S&P 5007,801.77-0.22%DOW51,179.87-0.66%NASDAQ27,538.69-0.22%BTC$82,323.00-1.41%ETH$2,533.48-1.48%GOLD$4,146.30+0.14%OIL$92.57+4.86%
Smart Investors Daily
SID Premium
Boundless Bio, Inc. logo

NASDAQ · BOLD

Boundless Bio, Inc.

Healthcare · Biotechnology

$2.64

Up+$0.07 (+2.72%)

Updated Oct 8, 2026, 12:48 PM

SID Score

4.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
25.74M
P/E ratio
-0.4
Dividend yield
0.00%
52-week range
$1.07 – $3.16
Volume
116.89K
Avg. volume
159.75K

Price performance · BOLD

BOLD price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

BOLD closed at $2.64 after 21 trading sessions, down 7.37% for the selected period.

Last close
$2.64
Period change
-7.37%
Period low
$2.51
Period high
$2.88
Daily close
View OHLC price history
BOLD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$2.58$2.71$2.562$2.64116.89K
Oct 6, 2026$2.62$2.65$2.515$2.5765.18K
Oct 5, 2026$2.62$2.66$2.56$2.6055.06K
Oct 2, 2026$2.62$2.70$2.55$2.62156.53K
Oct 1, 2026$2.49$2.62$2.49$2.59163.79K
Sep 30, 2026$2.56$2.635$2.42$2.51208.24K
Sep 29, 2026$2.60$2.62$2.56$2.5652K
Sep 28, 2026$2.68$2.715$2.558$2.61142.24K
Sep 25, 2026$2.61$2.67$2.59$2.66255.4K
Sep 24, 2026$2.69$2.74$2.595$2.60550.32K
Sep 23, 2026$2.89$2.89$2.685$2.70170.13K
Sep 22, 2026$2.93$2.93$2.83$2.8830.25K
Sep 21, 2026$2.80$2.835$2.75$2.83133.7K
Sep 18, 2026$2.79$2.87$2.77$2.81346.38K
Sep 17, 2026$2.83$2.83$2.77$2.8092.21K
Sep 16, 2026$2.81$2.85$2.785$2.82102.23K
Sep 15, 2026$2.83$2.85$2.81$2.8123.23K
Sep 14, 2026$2.84$2.89$2.8399$2.8429.83K
Sep 11, 2026$2.85$2.85$2.81$2.8363.84K
Sep 10, 2026$2.85$2.87$2.82$2.8428.65K
Sep 9, 2026$2.86$2.8781$2.83$2.8548.82K

Latest BOLD news

The latest Smart Investors Daily articles mentioning BOLD.

Stock researchCompany · Overview

BOLD research

Overview

Company profile and research snapshot.

Company profile

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$3.06
Implied upside
—
Analysts
—
BOLD recent ratings
DateFirmRatingTarget
Aug 11, 2025HC Wainwright & Co.Buy—
Jun 2, 2025HC Wainwright & Co.Buy—
May 28, 2025Leerink PartnersMarket Perform—
Dec 13, 2024GuggenheimNeutral—
Apr 22, 2024Leerink PartnersOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 28, 2026

Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer

Industry veteran brings more than two decades of oncology drug discovery leadership to advance Callio's dual-payload ADC pipelineSAN DIEGO and SEATTLE and SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics (“Callio” or “the Company”), a global, clinical-stage biotechnology company advancing dual-payload antibody-drug conjugates (ADCs) as the next frontier of rationally designed targeted cancer therapy, today announced the appointment of Chris Hassig, PhD, as Chief Scientific Offic

Yahoo · Sep 9, 2026

Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer

Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancer Piers Ingram, PhD, Co-Founder, transitions to Senior Advisor and continues to serve on the Board of Directors; Jerome Boyd-Kirkup, PhD, founding Chief Scientific Officer, transitions to Senior Scientific Advisor SAN DIEGO and SEATTLE and SINGAPORE, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics (“Callio” or “the Company”), a clinical-stage

Benzinga · Sep 9, 2026

Callio Therapeutics Appoints Zachary Hornby As CEO

Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancerPiers Ingram, PhD, Co-Founder, transitions to Senior Advisor and

Benzinga · Aug 10, 2026

Boundless Bio Q2 EPS $(1.06) Misses $(0.61) Estimate

Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.61) by 73.77 percent. This is a 51.43 percent decrease over losses of $(0.70) per share from

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By